ReviewNature reviews. Drug discovery2011
Quantifying factors for the success of stratified medicine.
Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways.Clinical pharmacology and therapeutics · 2026Review
- In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Facial expression recognition is linked to clinical and neurofunctional differences in autism.Molecular autism · 2022Article
- About gladiators and a sacred disease.Biomedical journal · 2022Article
- Article
- Computational Approaches Integrated in a Digital Ecosystem Platform for a Rare Disease.Frontiers in molecular medicine · 2022Review
- The meaning of significant mean group differences for biomarker discovery.PLoS computational biology · 2021Article
- Conversion from cilostazol to OPC-13015 linked to mitigation of cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.Frontiers in immunology · 2020Review
- Article
- Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?PharmacoEconomics · 2018Article
- Relationships of Ex-Vivo Drug Resistance Assay and Cytokine Production with Clinicopathological Features in the Primary Cell Culture of Thai Ovarian and Fallopian Tube Cancer PatientsAsian Pacific journal of cancer prevention : APJCP · 2017Article
- The Reactive Species Interactome: Evolutionary Emergence, Biological Significance, and Opportunities for Redox Metabolomics and Personalized Medicine.Antioxidants & redox signaling · 2017Review
- Toward Precision Healthcare: Context and Mathematical Challenges.Frontiers in physiology · 2017Article
- PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.Clinical pharmacology and therapeutics · 2016Article
- Pharmacogenomics of preterm birth prevention and treatment.BJOG : an international journal of obstetrics and gynaecology · 2016Review
- The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans.PLoS medicine · 2015Article
- A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.Frontiers in genetics · 2015Article
- From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.Frontiers in cell and developmental biology · 2014Article
- Therapeutic target database update 2014: a resource for targeted therapeutics.Nucleic acids research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-developing a drug with a diagnostic to create a stratified medicine - a therapy that is targeted to a specific patient population on the basis of a clinical characteristic such as a biomarker that predicts treatment response - presents challenges for product developers, regulators, payers and physicians. With the aim of developing a shared framework and tools for addressing these challenges, here we present an analysis using data from case studies in oncology and Alzheimer's disease, coupled with integrated computational modelling of clinical outcomes and developer economic value, to quantify the effects of decisions related to key issues such as the design of clinical trials. This illustrates how such analyses can aid the coordination of diagnostic and drug development, and the selection of optimal development and commercialization strategies. It also illustrates the impact of the interplay of these factors on the economic feasibility of stratified medicine, which has important implications for public policy makers.
Indexed as
Identifiers
22037040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.